Curanex Pharmaceuticals (CURX) EBT (2024 - 2025)
Curanex Pharmaceuticals' (CURX) quarterly EBT came in at -$3.1 million in Q4 2025, down 1014.65% YoY from $338121.5 in Q4 2024, and down 159.18% on a QoQ basis from -$1.2 million in Q3 2025.
Curanex Pharmaceuticals (CURX) EBT (2024 - 2025) Analysis & Trends
Curanex Pharmaceuticals (CURX) has 2 years of EBT data on file, last reported at -$3.1 million in Q4 2025.
- Quarterly EBT fell 1014.65% year-over-year to -$3.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$4.8 million (changed N/A YoY) and the FY2025 annual result came in at -$5.3 million, down 961.59% from the prior year.
- EBT fell to -$3.1 million in Q4 2025, from -$1.2 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$93295.0 in Q3 2024 to a low of -$3.1 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Curanex Pharmaceuticals | 6.11 Mn | 1.11 Mn | - | -3.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -3.09 Mn |
| Sep 30, 2025 | -1.19 Mn |
| Jun 30, 2025 | -229,310.00 |
| Dec 31, 2024 | -277,453.00 |
| Sep 30, 2024 | -93,295.00 |